Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05997056 · ClinicalTrials.gov registry record · Phase 2
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
A Phase 2 study of Neuroendocrine Tumors and Pancreatic Neuroendocrine Tumor, sponsored by Aadi Bioscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 4
- Study locations
NCT05997056 is a Phase 2 study of Neuroendocrine Tumors and Pancreatic Neuroendocrine Tumor that is actively recruiting participants, run by Aadi Bioscience. The registered enrollment target is 21 participants, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05997056, a Phase 2 study of Neuroendocrine Tumors and Pancreatic Neuroendocrine Tumor, is actively recruiting participants, sponsored by Aadi Bioscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 4
- Study locations
Study Summary
A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors
Conditions Studied
Interventions
- DRUG nab-sirolimus
Study Locations (4)
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
Colorado
- Rocky Mountain Cancer Centers - Denver
Texas
- Texas Oncology - Dallas
Wisconsin
- Medical College of Wisconsin Cancer Center - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-11-07 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05997056
The ClinicalTrials.gov registry entry for NCT05997056 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (88% lower). The listed sponsor is Aadi Bioscience, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which nab-sirolimus is the first listed.
NCT05997056 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Texas.
Frequently Asked Questions
What is clinical trial NCT05997056 about?
NCT05997056 is a clinical study titled "Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors". A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors
What is the current status of trial NCT05997056?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2023-11-07. Estimated completion is 2025-12-08.
What conditions does trial NCT05997056 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, NET, Gastrointestinal Neuroendocrine Tumor, Pulmonary Neuroendocrine Tumor.
What interventions are being tested in trial NCT05997056?
The interventions under investigation include: nab-sirolimus (DRUG).
Who is sponsoring clinical trial NCT05997056?
This trial is sponsored by Aadi Bioscience, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05997056 being conducted?
This trial has 4 study locations across California, Colorado, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
-
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.